Latest Industry News & Trends

Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz

Tarsus Pharmaceuticals, of Irvine, California, reported May 6 that its Q1-2026 revenue for Xdemvy was $145.4 million, an 85 percent increase over $78.3 million in Q1-2025. Xdemvy (lotilaner ophthal...

US FDA Commissioner Makary Resigns After Rocky Year in Top Job

US FDA Commissioner Marty Makary, MD, MPH, resigned May 12 after a rocky year in the agency’s top job that saw mass layoffs, high-level resignations, and policy fights with lawmakers, drugmakers, a...

IOP-Lowering Goggles Gain US FDA 510(k) Nod for Wireless Upgrade

Balance Ophthalmics announced May 12 that it had gained US FDA 510(k) clearance for a wireless-enabled, next-generation version of its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, design...

Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...

EU Softens Stance on MDR Transition to Ensure Availability of Needed Devices

Implementation of the European Union’s Medical Device Regulation (MDR) has proven more complex and prolonged than originally anticipated. The new standards took effect in May 2021, ending a four-ye...

Incremental Improvements are the Trend in Vitrectomy Systems

New retinal surgical device offerings from manufacturers feature innovative fluidics systems and stiffer small-gauge instruments. Manufacturers hope the improvements they bring to vitrectomy surger...

J&J Continues to Reduce JLABS Footprint with Exit from New York

Johnson & Johnson is stepping away from its JLABS incubator site in New York, reducing its JLABS locations in the US to those in San Diego, San Francisco, and Boston. The New York site opened in 20...

Bausch + Lomb Gains US FDA Clearance for Bi-Blade+ Cutter and Adaptive Fluidics Update

Bausch + Lomb announced April 8 that the US FDA had granted 510(k) clearance for the Bi-Blade+ dual-port cutter and Adaptive Fluidics update for the Stellaris Elite dual-function cataract and vitre...

Halma Acquires Surgistar to Augment MST’s Ophthalmic Instrument Portfolio

UK-based Halma, the parent of ophthalmic instrument maker MicroSurgical Technology (MST) announced April 13 that it had acquired Surgistar, of Vista, California, as an add-on to MST. No financial d...

US FDA Gives Green Light to Trial of i-Lumen’s Bioelectric Stimulation Device for Dry AMD

i-Lumen Scientific announced March 31 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a pivotal trial of its bioelectri...

J&J Continues to Reduce JLABS Footprint with Exit from New York

Johnson & Johnson is stepping away from its JLABS incubator site in New York, reducing its JLABS locations in the US to those in San Diego, San Francisco, and Boston. The New York site opened in 20...

Ophthalmic Company Revenue Down 1.8 Percent in Q4-2025; Seven Firms See Declines

Ophthalmic manufacturer revenue in Q4-2025 totaled $11.8 billion. Revenue decreased 1.8 percent from the same quarter in 2024 and increased 2.5 percent from Q3-2025. The total includes Market Scope...

Science Corp. Leads Latest Fundraising with $230 Million in Series C

Science Corporation led recent ophthalmic fundraising efforts with $230 million in a Series C round to support its Prima implant for dry age-related macular degeneration. Financing announced in the...

Weekly Poll of MDs and ODs, March 2026

Super Vision Gains China Approval of i-NYS Implant for Congenital Nystagmus

China-based Super Vision reported March 16 that its i-NYS implantable device forcongenital nystagmus had received market approval from China’s National Medical Products Administration (NMPA). Super...

EU-India Free Trade Agreement to Phase in Lower Pharma and Device Tariffs

A free trade agreement reached Jan. 27 by the European Union and India will reduce or eliminate tariffs on about 90 percent of goods, including pharmaceuticals and medical devices, between the two ...

EU-India Free Trade Agreement to Phase in Lower Pharma and Device Tariffs

A free trade agreement reached Jan. 27 by the European Union and India will reduce or eliminate tariffs on about 90 percent of goods, including pharmaceuticals and medical devices, between the two ...

2025 in Review: Alcon Launches Two New Platforms, Unity and Voyager

Ophthalmic industry leader Alcon launched the Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) in April 2025. The devices are designed to replace Alcon’s Constellation dual-...

Meibum Scientific Appoints Ryan S. Bleeks as Interim CEO

Meibum Scientific, of Brentwood, Tennessee, announced Dec. 2 that it had appointed Ryan S. Bleeks as interim chief executive officer to lead the commercialization of dry eye treatment devices Bleph...

Dry Eye Device Field Gets More Crowded With Product Launches

The dry eye procedure market is relatively small, but barriers to entry are low, and that is attractive for new competitors. Asian companies, from China and South Korea, launched new machines in th...

Iantrek Announces US Commercial Launch of AlloFlo Uveo Biostent for Glaucoma

Iantrek announced Oct. 14 the US commercial launch of the AlloFlo Uveo, a novel minimally invasive glaucoma surgical (MIGS) device targeting the uveoscleral drainage pathway. The AlloFlo Uveo allog...

US FDA Gives Green Light to Trial of Avisi’s VisiPlate Aqueous Shunt for Glaucoma

Avisi Technologies announced Oct. 14 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of the VisiPlate aqueous s...

Euretina Presentations Included Surprises on Vitreous Cutters, PBM Treatment

Doctors who attend the annual Euretina congress often hear paper presentations similar to those at the American Society of Retina Specialists meeting, but sessions also provide important difference...

First Patient Treated in US Trial of Eyetronic Optic Nerve Therapy for Glaucoma

The Glaucoma Center of San Francisco announced July 21 that it had treated the first patient in the US as part of a clinical trial of Eyetronic, a non-invasive therapy to stimulate the optic nerve....

Alcon to Acquire LumiThera and Its Photobiomodulation Device for Dry AMD

Alcon announced July 7 that it intended to acquire LumiThera and its photobiomodulation (PBM) device that targets early and intermediate dry age-related macular degeneration (AMD). No financial det...

Malvina Eydelman, MD, Named CEO of CCOI Organization

Longtime US FDA regulator and board-certified ophthalmologist Malvina Eydelman, MD, has stepped into a new role as chief executive officer of the Collaborative Community on Ophthalmic Innovation (C...

Malvina Eydelman, MD, Named CEO of CCOI Organization

Longtime US FDA regulator and board-certified ophthalmologist Malvina Eydelman, MD, has stepped into a new role as chief executive officer of the Collaborative Community on Ophthalmic Innovation (C...

Retina Surgeons Ready for Alcon to Make a Splash with Unity VCS

Alcon looks ready to shake up the retinal treatment device market with the launch of the Unity VCS later in 2025. Anytime the world’s number one manufacturer of vitreoretinal surgical systems intro...